Innate Pharma's book value per share for the quarter that ended in Dec. 2025 was $-0.27.
During the past 12 months, Innate Pharma's average Book Value Per Share Growth Rate was -321.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Innate Pharma was 29.50% per year. The lowest was -57.30% per year. And the median was -0.30% per year.
Innate Pharma's current price is $1.80. Its book value per share for the quarter that ended in Dec. 2025 was $-0.27. Hence, today's PB Ratio of Innate Pharma is .
During the past 13 years, the highest P/B Ratio of Innate Pharma was 20.95. The lowest was 1.11. And the median was 3.20.
Innate Pharma (NAS:IPHA) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Innate Pharma Book Value per Share Related Terms
Innate Pharma Book Value per Share Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Innate Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Innate Pharma's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Book Value per Share of $-0.27 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Innate Pharma and its competitors.
Is Innate Pharma's Book Value per Share too high?
Innate Pharma's current Book Value per Share is $-0.27. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Book Value per Share compare to VRTX and REGN?
Innate Pharma's Book Value per Share of $-0.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Innate Pharma and its competitors. Innate Pharma's current Book Value per Share is $-0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.80 — trading 1100% above its estimated fair value. The current Book Value per Share is $-0.27. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Book Value per Share is $-0.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.80 is trading 1100% above its estimated GF Value™ of $0.15.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Book Value per Share: $-0.27
GF Value™: $0.15 vs. price of $1.80 (1100% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
